| Zhang, Chunlei |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Completed | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 08/24 | 08/24 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05531682: A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 2 | 160 | RoW | Placebo, HB0017, HB0017 dosing regimens | Huabo Biopharm Co., Ltd. | Plaque Psoriasis | 05/23 | 01/24 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment |
|
|
| Recruiting | 2 | 200 | RoW | LP-003, Placebo, Omalizumab | Longbio Pharma | Chronic Spontaneous Urticaria | 01/25 | 01/25 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
AMITY, NCT06436677: A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma |
|
|
| Recruiting | N/A | 100 | RoW | molecular subtype based treatment | Peking University First Hospital, Peking University Third Hospital, Peking University Cancer Hospital & Institute | Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma | 12/26 | 12/30 | | |
| Recruiting | N/A | 3000 | RoW | | Peking University First Hospital | Primary Cutaneous Lymphoma | 08/32 | 08/32 | | |
| Guan, Xin |
MET-LVH, NCT05719337: Multi-Modality Echocardiographic Techniques in Pathological Left Ventricular Hypertrophy Adults |
|
|
| Recruiting | N/A | 660 | RoW | Echocardiography | First Hospital of China Medical University, Wuhan Union Hospital, China | Left Ventricular Hypertrophy | 08/24 | 08/25 | | |
NOVAEA-HFUS, NCT05970926: Normal Reference Values in Han Adults of Extremity Arterial Structure and Hemodynamics by High-frequency Ultrasound |
|
|
| Not yet recruiting | N/A | 540 | NA | high-frequency ultrasound | First Hospital of China Medical University | Healthy Volunteer, Artery Disease | 08/24 | 08/25 | | |
NOVAS-HFUS, NCT06000163: Normal Reference Values in Han Adults of Skin Thickness and Blood Flow by High-frequency Ultrasound |
|
|
| Not yet recruiting | N/A | 540 | NA | high-frequency ultrasound | First Hospital of China Medical University | Healthy Volunteer, Skin | 09/24 | 09/25 | | |
NCT04440683: Antler Plate on Preventing Mammary High-risk Lesions From Malignant Development |
|
|
| Recruiting | N/A | 6000 | RoW | | Jilin University | Breast Cancer Prevention | 05/22 | 06/25 | | |
| Li, Chunting |
NCT05785806: Parent Infant Skin-to-Skin Contact Intervention Based on The Co-parenting Theory |
|
|
| Completed | N/A | 111 | RoW | Skin to skin contact and co-parenting theory course, Skin to skin contact instruction manual and co-parenting theory brochure, Daily face-to-face skin to skin contact guidance during hospitalization, Online punching skin to skin contact, Routine obstetric care | Affiliated Hospital of Jiangnan University | Postpartum Anxiety, Parturition; Precipitate | 10/23 | 01/24 | | |
| Wang, Wenhui |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
| Li, Zhengnan |
| No trials found |
